Related Experiment Video
Updated: Dec 9, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Delta-like Factor 1 as a Possible Therapeutic Target for Sarcomas
Han-Soo Kim1,2, Sun Hee Ahn1, Ha Jeong Kim1
1Department of Orthopedic Surgery, Seoul National University Hospital, Seoul, Korea.
Backgroud:
Cancer stem cells (CSCs) are cells characterized by their self-renewal and tumorigenic potential. The purpose of this study was to discover the role of the delta-like factor 1 (DLK1) in sarcoma.
Methods:
mRNA expression of DLK1 from 13 sarcoma cell lines was examined. Isolated CSCs from the tumors were examined using fluorescence-activated cell sorting (FACS) with CD133, the CSC marker, or sphere-forming assay. The relationship between DLK1 and CSCs in sarcoma was examined using cell proliferation and cell invasion assays after they were treated with DLK1 short interfering RNA (siRNA).
Results:
A high expression of DLK1 mRNA was observed in all sarcoma cell lines. However, CSCs were isolated from over expressed sarcomas of the DLK1 gene, and they have shown to be expressed lower than the wild type. The anti-cancer effects of DLK1 siRNA inhibited cell proliferation and invasion in U2OS, A204, and sw872. In addition, treatment with DLK1 siRNA inhibited cell invasion in sw872 CSCs. DLK1 gene induces tumorigenesis in various sarcoma cells and regulates the invasiveness of liposarcoma. These results suggest that DLK1 could serve as a possible therapeutic target for sarcoma.
Conclusions:
Our study showed that the DLK1 gene induces tumorigenesis in various sarcomas and is associated with invasive mechanism in sarcoma. These results suggest DLK1 could serve as a possible therapeutic target in a variety of sarcomas.
Insights
The delta-like factor 1 (DLK1) gene promotes sarcoma growth and invasion. Inhibiting DLK1 showed anti-cancer effects, suggesting DLK1 as a potential therapeutic target for sarcoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Cancer stem cells (CSCs) possess self-renewal and tumorigenic capabilities.
- Sarcomas are a diverse group of cancers originating from connective tissues.
Purpose of the Study:
- To investigate the role of delta-like factor 1 (DLK1) in sarcoma development and progression.
- To explore DLK1 as a potential therapeutic target in sarcoma.
Main Methods:
- Examined DLK1 mRNA expression in 13 sarcoma cell lines.
- Isolated and analyzed CSCs using fluorescence-activated cell sorting (FACS) and sphere-forming assays.
- Assessed the impact of DLK1 inhibition via short interfering RNA (siRNA) on sarcoma cell proliferation and invasion.
Main Results:
- High DLK1 mRNA expression was detected across all sarcoma cell lines.
- CSCs isolated from DLK1-overexpressing sarcomas showed lower DLK1 expression than wild-type cells.
- DLK1 inhibition suppressed proliferation and invasion in multiple sarcoma cell lines, including CSCs, and regulated liposarcoma invasiveness.
Conclusions:
- The DLK1 gene drives tumorigenesis and contributes to the invasive mechanisms in various sarcomas.
- DLK1 represents a promising therapeutic target for sarcoma treatment.
Related Concept Videos
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against...
Regulation of Angiogenesis and Blood Supply
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:

